Accretion Pharmaceuticals Limited (NSE:ACCPL)
India · Delayed Price · Currency is INR 202.50
-9.50 (-4.48%)
At close: Nov 6, 2026
Accretion Pharmaceuticals Revenue
Accretion Pharmaceuticals had revenue of 457.81M INR in the half year ending March 31, 2026. This brings the company's total for the last twelve months to 1.01B, up 22.17% year-over-year. In the fiscal year ending March 31, 2026, Accretion Pharmaceuticals had annual revenue of 896.27M with 56.21% growth. That makes Accretion Pharmaceuticals the 37,052nd largest company in the world by revenue and 3,230th in India.
Revenue (ttm)
1.01B
Revenue Growth
+22.17%
P/S Ratio
2.23
Revenue / Employee
7.65M
Employees
132
Market Cap
2.25B
Revenue by Geography
- India 819.63M 91.4%
- outside India 76.64M 8.6%
Fiscal year ended Mar 31, 2026 See the full Accretion Pharmaceuticals breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 896.27M | 322.51M | 56.21% |
| Mar 31, 2025 | 573.76M | 440.24M | 329.70% |
| Mar 31, 2024 | 133.53M | -161.79M | -54.79% |
| Mar 31, 2023 | 295.32M | 69.47M | 30.76% |
| Mar 31, 2022 | 225.84M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bilcare | 8.38B |
| Sat Kartar Life | 2.24B |
| Ambalal Sarabhai Enterprises | 2.06B |
| Everest Organics | 1.92B |
| Gennex Laboratories | 1.78B |
| Kerala Ayurveda | 1.36B |
| Oxygenta Pharmaceutical | 1.35B |
| BDH Industries | 997.10M |